Is mild hypernatremia an independent predictor of poor clinical outcome in neurocritically ill patients?

Yun Im Lee
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Joonghyun Ahn
Statistic and data center, Clinical Research Institute, Samsung Medical Center

Jeong-Am Ryu (λ lamyud.ryu@samsung.com)
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Research Article

Keywords: hypernatremia, neurocritically ill, hyperosmolar therapy

Posted Date: December 9th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-116867/v1

License: © ① This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

We investigated the impact of hypernatremia on mortality of neurocritically ill patients. Among neurosurgical patients admitted to the intensive care unit (ICU) from January 2013 to December 2019, the patients who were hospitalized in the ICU for more than 5 days included. Hypernatremia was defined as the highest serum sodium level exceeding 150 mEq/L observed. Among 1,146 patients, 353 patients (30.8%) showed hypernatremia. Based on propensity score matching, 290 pairs were analyzed. Hypernatremia group had higher rates of in-hospital mortality compared with non-hypernatremia group in overall and matched population ($p < 0.001$ and $p = 0.001$, respectively). In multivariable analysis of propensity score-matched population, moderate and severe hypernatremia were significantly associated with in-hospital mortality (adjusted odds ratio [OR]: 4.58, 95% confidence interval [CI]: 2.15 – 9.75 and adjusted OR: 6.93, 95% CI: 3.46 – 13.90, respectively) compared with the absence of hypernatremia. However, in-hospital mortality was not significantly different between non-hypernatremia and mild hypernatremia groups ($p = 0.720$). Interestingly, mild hypernatremia group of matched population showed the best survival rate. Eventually, moderate and severe hypernatremia were associated with poor clinical outcomes in neurocritically ill patients. However, prognosis of the patients with mild hypernatremia was similar with those without hypernatremia.

Introduction

Hypernatremia is routinely detected in intensive care units (ICUs) and more frequently in the neurosurgical ICU than in the general ICU. Hypernatremia may be associated with various complications in critically ill patients. Therefore, ICU-acquired hypernatremia is associated with poor clinical outcomes in critically ill patients.

Hypernatremia is caused by increased sodium intake, loss of free water, or both. Under normal conditions, thirst is the primary defense mechanism against the development of hypernatremia. However, this mechanism is disrupted in critically ill patients because their consciousness is generally disturbed by sedation or delirium. Moreover, neurocritically ill patients are more likely to develop hypernatremia than patients in general ICUs for several reasons, including impaired thirst mechanisms, altered mentality, and hormonal abnormalities resulting from brain injury. In addition, hypernatremia may be induced by treating elevated intracranial pressure (ICP) with hyperosmolar therapies, such as mannitol and hypertonic saline, and control of ICP may be correlated with serum sodium concentration. However, it is unclear whether hypernatremia can be prevented in patients with intracranial hypertension, even by reducing or discontinuing hyperosmolar agents.

A limited number of studies reported that clinical outcomes correlated with the severity of hypernatremia in neurocritically ill patients. It is unknown whether hypernatremia itself is associated with poor prognosis, or is a symptom associated with neurocritical illness. Therefore, the objective of this study was to investigate the impact of hypernatremia on mortality of neurocritically ill patients, depending on the degree of hypernatremia. In addition, we evaluated whether hypernatremia per se was associated with poor prognosis when severity and factors other than hypernatremia were controlled by propensity score matching.

Methods

Study population.

This is a retrospective, single-center, observational study. Patients admitted to the neurosurgical ICU in a tertiary, referral hospital (Samsung Medical Center, Seoul, Republic of Korea) from January 2013 to December 2019 were eligible. This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: 2020-09-082). The requirement for informed consent was waived due to the study's retrospective nature. We included patients (1) who were hospitalized in the ICU for more than 5 days, (2) those who died within 5 days after ICU admission, and (3) whose serum sodium concentrations were obtained during the ICU admission. We excluded patients (1) with hypernatremia (serum sodium > 150 mEq/L) on ICU admission, (2) with insufficient medical records, (3) those who were admitted to departments other than neurosurgery, and (4) those who were transferred to other hospitals and with unknown prognoses (Fig. 1).
Definitions and endpoints.

In this study, baseline characteristics of comorbidities, ICU management, and laboratory data were collected retrospectively using Clinical Data Warehouse. Our center constructed the “Clinical Data Warehouse Darwin-C” designed for investigators to search and retrieve de-identified medical records from the electronic archives. It contains data pertaining to more than four million patients. The clinical and laboratory data were extracted from the Clinical Data Warehouse Darwin-C after finalizing the patient list in this study. The levels of serum sodium were measured at least once every morning in all patients. Additional laboratory tests were performed if patients underwent hyperosmolar therapy or when attending physicians or neurosurgeons needed additional tests throughout the day. Hypernatremia was defined as the highest serum sodium level exceeding 150 mEq/L during ICU stay. We also classified the patients to determine the association between clinical outcomes and severity of hypernatremia. Patients were divided into four subgroups: no hypernatremia (≤150 mEq/L), mild hypernatremia (151 – 155 mEq/L), moderate hypernatremia (156 – 160 mEq/L), and severe hypernatremia (>160 mEq/L). Acute Physiology and Chronic Health Evaluation (APACHE) II score was calculated with worst values recorded during the initial 24 h in the ICU admission. If the patient was intubated, the verbal score of Glasgow Coma Scale (GCS) was estimated using the eye and motor scores as reported previously. The primary endpoint was in-hospital mortality and the secondary outcome was 28-day mortality.

Statistical analyses.

All data are presented as means ± standard deviations for continuous variables and frequencies and proportions for categorical variables. Data were compared using Student’s t-test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables.

Propensity score matching was used to control the selection bias and the confounding detected in this observational study. Each patient with hypernatremia was matched to one of the control patients with the nearest neighbor matching within calipers determined by the propensity score. A caliper width of 0.2 of the standard deviation of the logit of the propensity score was used for the matching. To determine the effectiveness of propensity score matching in controlling the differences between patients with and without hypernatremia, the standardized mean differences (SMDs) were calculated for each variable before and after matching. SMDs less than 10% were considered successful propensity scores matching and balancing the groups.

To conduct doubly robust estimation to improve causal inference, we combined the propensity score matching and regression methods. The propensity score-matched population was subjected to multiple logistic regression analysis with stepwise variable selection. The variables included in the propensity score estimation and the other multivariable analyses were age, sex, comorbidities, cause of ICU admission, utilization of organ support modalities, including mechanical ventilators, continuous renal replacement therapy and vasopressors, invasive ICP monitoring devices, hyperosmolar therapy, GCS, and APACHE II score on ICU admission. The cumulative incidences of mortality were calculated by Kaplan–Meier estimates and compared using a log-rank test. All tests were two-sided and p values less than 0.05 were considered statistically significant. Statistical analyses were performed with R Statistical Software (version 4.0.2; R Foundation for Statistical Computing, Vienna, Austria).

Results

Baseline characteristics.

A total of 12,743 patients were admitted to the neurosurgical ICU during the study period and 1,146 patients were included in the analysis. In the study population, 353 patients (30.8%) had hypernatremia (Fig. 1). Mean age of all patients was 50.0 ± 22.9 years. The study included 597 (52.1%) male patients. Malignancy (56.4%) and hypertension (34.1%) were the most common comorbidities. Brain tumors (39.1%) and intracerebral hemorrhage (18.2%) were the most common reasons for ICU admission. Age and APACHE II score on ICU admission were higher in patients with hypernatremia compared with those without hypernatremia (both p < 0.001). However, malignancy was more common in the group with hypernatremia than in the group
without \( p < 0.001 \). Vasopressors and mechanical ventilators were more commonly used in patients with hypernatremia compared with those without hypernatremia (both \( p < 0.001 \)). Although the frequency of mannitol use was similar between the two groups \( (p = 0.293) \), glycerin was more frequently used in the hypernatremia group \( (p < 0.001) \). The mean value of maximum serum sodium level was higher in the hypernatremia group than in the group without hypernatremia \((160.2 \pm 8.6 \text{ mEq/L vs. } 141.9 \pm 5.8 \text{ mmol/L, } p < 0.001)\). The mean value of minimum serum sodium level was also higher in the hypernatremia group than in the non-hypnatremia group \((144.3 \pm 12.9 \text{ mEq/L vs. } 135.1 \pm 5.8 \text{ mEq/L, } p < 0.001)\). However, there were no significant differences in the length of stay in the ICU and hospital between the two groups \((p = 0.970 \text{ and } p = 0.232, \text{ respectively})\).

After propensity score matching, 290 pairs of data were generated by 1:1 individual matching without replacement. No significant imbalance was found in the baseline characteristics between the matched data pairs (Table 1).
| Table 1                                                                 |
|-----------------------------------------------------------------------|
| Baseline characteristics of study population.                         |
| Overall study population                                              |
| Propensity score-matched population                                   |
| **No hypernatremia \( (n = 793) \)**                                  |
| **Hypernatremia \( (n = 353) \)**                                    |
| **\( P \) value**                                                    |
| **SMD**                                                               |
| **No hypernatremia \( (n = 290) \)**                                  |
| **Hypernatremia \( (n = 290) \)**                                    |
| **\( P \) value**                                                    |
| **SMD**                                                               |
| **Age (year)**                                                        | 47.5 ± 23.8 | 55.8 ± 19.6 | < 0.001 | 0.381 | 54.0 ± 19.4 | 54.7 ± 20.0 | 0.678 | 0.035 |
| **Sex, male**                                                         | 423 (53.3) | 174 (49.3) | 0.229 | 0.081 | 146 (50.3) | 143 (49.3) | 0.868 | 0.021 |
| **Comorbidities**                                                     |              |            |        |       |              |            |       |
| **Malignancy**                                                        | 486 (61.3) | 160 (45.3) | < 0.001 | 0.324 | 137 (47.2) | 143 (49.3) | 0.678 | 0.041 |
| **Hypertension**                                                      | 258 (32.5) | 133 (37.7) | 0.104 | 0.108 | 103 (35.5) | 103 (35.5) | 0.999 | < 0.001 |
| **Diabetes mellitus**                                                 | 91 (11.5) | 62 (17.6) | 0.007 | 0.173 | 49 (16.9) | 47 (16.2) | 0.911 | 0.019 |
| **Chronic kidney disease**                                            | 56 (7.1) | 24 (6.8) | 0.972 | 0.010 | 23 (7.9) | 20 (6.9) | 0.751 | 0.039 |
| **Cardiovascular disease**                                            | 30 (3.8) | 15 (4.2) | 0.833 | 0.024 | 14 (4.8) | 12 (4.1) | 0.841 | 0.033 |
| **Chronic liver disease**                                             | 28 (3.5) | 12 (3.4) | 0.999 | 0.007 | 10 (3.4) | 10 (3.4) | 0.999 | < 0.001 |
| **Habitual risk factors**                                             |              |            |        |       |              |            |       |
| **Current alcohol consumption**                                       | 156 (19.7) | 95 (26.9) | 0.008 | 0.172 | 73 (25.2) | 73 (25.2) | 0.999 | < 0.001 |
| **Current smoking**                                                   | 83 (10.5) | 47 (13.3) | 0.193 | 0.088 | 34 (11.7) | 35 (12.1) | 0.999 | 0.011 |
| **Cause of ICU admission**                                            |              |            |        |       |              |            |       |
| **Brain tumor**                                                       | 356 (44.9) | 92 (26.1) | < 0.001 | 0.503 | 82 (28.3) | 88 (30.3) |       |       |
| **Intracerebral hemorrhage**                                          | 123 (15.5) | 85 (24.1) |          |       | 63 (21.7) | 69 (23.8) |       |       |
| **Traumatic brain injury**                                            | 89 (11.2) | 67 (19.0) |          |       | 54 (18.6) | 47 (16.2) |       |       |
| **Subarachnoid hemorrhage**                                           | 90 (11.3) | 61 (17.3) |          |       | 42 (14.5) | 43 (14.8) |       |       |
| **Elective vascular surgery**                                         | 72 (9.1) | 19 (5.4) |          |       | 19 (6.6) | 17 (5.9) |       |       |
| **Cerebral infarction**                                               | 17 (2.1) | 13 (3.7) |          |       | 11 (3.8) | 10 (3.4) |       |       |
| **Central nervous system infection**                                  | 16 (2.0) | 3 (0.8) |          |       | 4 (1.4) | 3 (1.0) |       |       |
### APACHE II score on ICU admission

|            | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value |
|------------|------------|---------|------------|---------|------------|---------|------------|---------|
|             |            |         |            |         |            |         |            |         |
|            | 6.28 ± 6.2 | < 0.001 | 4.36       | 0.373   | 7.84 ± 7.3 | 0.074  | 8.40 ± 7.7 | 0.077   |

### Glasgow coma scale on ICU admission

|            | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value |
|------------|------------|---------|------------|---------|------------|---------|------------|---------|
|             |            |         |            |         |            |         |            |         |
|            | 13.3 ± 3.2 | < 0.001 | 11.62 ± 4.3 | 0.516   | 11.39 ± 4.4 | 0.054  | 10.5 ± 4.6  | 0.695   |

### ICU management

|                                | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value | Mean ± SD  | p-value |
|--------------------------------|------------|---------|------------|---------|------------|---------|------------|---------|
| Mechanical ventilation         | 291 (82.4) | < 0.001 | 122 (42.1) | 0.373   | 237 (81.7) | 0.074  | 149 (42.2) | 0.034   |
| Invasive ICP monitoring        | 122 (42.1) | 131 (45.2) | 0.503 | 0.063 | 0.087 | 0.064 |
| Continuous renal replacement therapy | 14 (4.8) | 0.999 | 13 (4.5) | 0.016 | 0.016 | 0.016 |

### Clinical outcomes

In the overall study population, the rates of in-hospital mortality and 28-day mortality were higher in the hypernatremia group compared with the non-hypernatremia group (45.6% vs. 15.5% and 43.6% vs. 13.5%, both p < 0.001) (Table 1). Clinical outcomes in the propensity score-matched population were similar with those of the entire population. In the propensity score-matched population, the rates of in-hospital mortality and 28-day mortality were also higher in the hypernatremia group compared with the non-hypernatremia group (40.3% vs. 26.9% and 37.9% vs. 24.8%, both p = 0.001) (Table 1).
In multivariable analysis of propensity score-matched population, the clinical outcomes, including in-hospital mortality and 28-day mortality, were not significantly different between non-hypernatremia and mild hypernatremia groups (\(p = 0.720\) and \(p = 0.690\), respectively) (Table 2). However, moderate and severe hypernatremia were significantly associated with in-hospital mortality (adjusted odds ratio [OR]: 4.58, 95% confidence interval [CI]: 2.15 – 9.75 and adjusted OR: 6.93, 95% CI: 3.46 – 13.90, respectively) and 28-day mortality (adjusted OR: 3.51, 95% CI: 1.54 – 7.98 and adjusted OR: 10.60, 95% CI: 5.10 – 21.90, respectively) compared with the absence of hypernatremia (Table 2). Finally, multivariable logistic regression analysis revealed that moderate and severe hypernatremia, use of vasopressors (adjusted OR: 3.07, 95% CI: 1.68 – 5.61), continuous renal replacement therapy (adjusted OR: 5.49, 95% CI: 1.80 – 16.70), and GCS on ICU admission (adjusted OR: 0.63, 95% CI: 0.59 – 0.68) were associated with in-hospital mortality (Table 2).

### Table 2

Multivariable analysis of clinical outcomes according to the severity of hypernatremia between propensity score matched population

**(A) In-hospital mortality**

| Hypernatremia                              | *Adjusted odds ratio (95% CI) | \(P\) value |
|--------------------------------------------|------------------------------|-------------|
| No hypernatremia                           | 1                            | Reference   |
| Mild hypernatremia                         | 0.88 (0.43 - 1.80)           | 0.720       |
| Moderate hypernatremia                     | 4.58 (2.15 - 9.75)           | < 0.001     |
| Severe hypernatremia                       | 6.93 (3.46 - 13.90)          | < 0.001     |
| Use of vasopressors                        | 3.07 (1.68 - 5.61)           | < 0.001     |
| Continuous renal replacement therapy       | 5.49 (1.80 - 16.70)          | 0.003       |
| Glasgow coma scale on admission            | 0.63 (0.59 - 0.68)           | < 0.001     |

* Adjusted for age, sex, comorbidities, cause of ICU admission, utilization of organ support modalities, use of invasive ICP monitoring device, hyperosmolar therapy, and APACHE II score

**APACHE II Acute Physiology and Chronic Health Evaluation, ICP intracranial pressure, ICU intensive care unit**

**(B) 28-day mortality**

| Hypernatremia                              | *Adjusted odds ratio (95% CI) | \(P\) value |
|--------------------------------------------|------------------------------|-------------|
| No hypernatremia                           | 1                            | Reference   |
| Mild hypernatremia                         | 0.86 (0.39 - 1.86)           | 0.690       |
| Moderate hypernatremia                     | 3.51 (1.54 - 7.98)           | 0.003       |
| Severe hypernatremia                       | 10.60 (5.10 - 21.90)         | < 0.001     |
| Use of vasopressors                        | 2.76 (1.47 - 5.16)           | 0.002       |
| Invasive ICP monitoring                     | 0.46 (0.26 - 0.83)           | 0.010       |
| Glasgow coma scale on admission            | 0.64 (0.59 - 0.69)           | < 0.001     |

* Adjusted for age, sex, comorbidities, cause of ICU admission, utilization of organ support modalities, use of invasive ICP monitoring device, hyperosmolar therapy, and APACHE II score

**APACHE II Acute Physiology and Chronic Health Evaluation, ICP intracranial pressure, ICU intensive care unit**
In survival analysis, the mortality rates of patients with moderate and severe hypernatremia were significantly higher compared with those with mild hypernatremia and without hypernatremia in the overall population and propensity score-matched population (Fig. 2). Especially, the mild hypernatremia group of matched population showed the best survival rate in the Kaplan-Meier curve. However, the mortality rate of patients with mild hypernatremia was not significantly lower compared with those without hypernatremia (16.1% vs. 27.6%, log-rank test, \( p = 0.163 \)).

**Discussion**

In this study, we investigated the severity and impact of hypernatremia on mortality of neurocritically ill patients, depending on the degree of hypernatremia. Major findings of this study were as follows. First, poor clinical outcomes were more common in patients with hypernatremia compared with those without hypernatremia in overall and propensity score-matched population. Second, patients with mild hypernatremia in the matched population showed the best survival rate. Finally, multivariable analysis revealed that moderate and severe hypernatremia, use of vasopressors and GCS on ICU admission were significantly associated with in-hospital mortality and 28-day mortality in neurocritically ill patients. Specifically, mild hypernatremia was not associated with poor clinical outcomes in this study.

In neurocritically ill patients, hyperosmolar therapy, including mannitol, glycerin or hypertonic saline, are frequently used to control intracranial hypertension. Hypernatremia may occur due to the use of these agents. Mild hypernatremia is the goal of serum sodium when hypertonic saline is used to lower ICP continuously. Neurocritically ill patients are frequently subjected to hyperosmolar therapy. Hyperosmolar therapy and associated acute kidney injury can aggravate hypernatremia. In addition, hypothalamic dysfunction due to brain injury can contribute to hypernatremia. Therefore, hypernatremia occurs easily in patients with severe neurological disease compared with those manifesting benign disease. Eventually, it is not easy to determine whether hypernatremia itself is associated with a poor prognosis, or patients with hypernatremia show poor prognosis because of their neurocritical illness. Therefore, a propensity score matching method was used to adjust for this confounder in this study. In brief, moderate and severe hypernatremia were significantly associated with poor clinical outcomes in neurocritically ill patients.

The prevalence of ICU-acquired hypernatremia was about 5.7% to 50.7% in previous studies. Hypernatremia and its associated hyperosmolar conditions lead to metabolic derangement and organ dysfunction, including abnormal hepatic gluconeogenesis, decreased lactate clearance, increased insulin resistance of peripheral tissues, cardiac dysfunction, muscle cramps and rhabdomyolysis. Therefore, hypernatremia itself may be associated with multiple complications, prolonged ICU stay, or even death. In addition, hypernatremia leads to increased cellular dehydration and decreased cerebral edema, which are often the therapeutic goals in neurocritical care. However, these homeostatic changes can injure myelin and even cause neuronal death. Thus, hypernatremia leads to additional secondary brain injury. Eventually, hypernatremia is also associated with poor clinical prognosis in neurocritically ill patients.

In this study, neurocritically ill patients with mild hypernatremia did not manifest worse outcomes compared to those without hypernatremia. However, patients with moderate or severe hypernatremia had worse prognosis than those without hypernatremia. In neurocritically ill patients with mild hypernatremia, favorable clinical outcomes may be associated with the ICP-lowering effect induced by mild hypernatremia with fewer complications than those detected during moderate and severe hypernatremia. Therefore, hyperosmolar agents may not be reduced or discontinued to maintain normal level of serum sodium in case of mild hypernatremia during treatment of patients with intracranial hypertension.

This study has several limitations. First, this was a retrospective review of medical records and the data extracted from Clinical Data Warehouse. The nonrandomized nature of registry data may have resulted in selection bias. Laboratory studies, including serum sodium levels, were not protocol-based. Second, hypernatremia was easily induced with hypertonic saline. Although, a small number of patients used hypertonic saline in this study, they could not be identified from Clinical Data Warehouse due to technical challenges. Third, the distribution of neurosurgical diseases differed from that of the general neurosurgical ICU, and the proportion of patients with brain tumors was particularly high. Although this study still provides valuable insight,
prospective large-scale studies are needed to confirm the safety and effectiveness of mild hypernatremia in neurocritically ill patients to arrive at evidence-based conclusions.

Conclusions

In this study, moderate and severe hypernatremia were associated with poor clinical outcomes in neurocritically ill patients. However, prognosis of the patients with mild hypernatremia was similar with those without hypernatremia. Therefore, mild hypernatremia may be allowed during the active management of intracranial hypertension using hyperosmolar therapy. Further, it may not be necessary to reduce or discontinue hyperosmolar agents to control mild hypernatremia.

Declarations

Acknowledgments

We would like to thank the nursing director of the neurosurgical intensive care unit, Hye Jung Kim, for their excellent advice and fruitful discussions. We also thank all nurses of the neurosurgical intensive care unit at Samsung Medical Center.

Funding

Not applicable.

Contributions

YIL contributed to the study design, data collection, drafting of the manuscript, and statistical analysis. JA contributed to the study design and statistical analysis. JAR contributed to the study conception and design, data collection, and drafting of the manuscript. All authors read and approved the final manuscript.

Ethics declarations

This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: SMC 2020-09-082). Patients’ records were reviewed and published according to the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of this study.

Competing interests

The authors declare no competing interests.

Consent for publication

Not applicable. This study does not contain individual or personal data in any form (including individual details, images, or videos).

Data availability

Our data are available on the Harvard Dataverse Network (http://dx.doi.org/10.7910/DVN/LVJEDX).

References
1. Lindner, G. et al. Hypernatremia in the critically ill is an independent risk factor for mortality. *Am. J. Kidney Dis.* **50**, 952-957, http://doi.org/10.1053/j.ajkd.2007.08.016 (2007).

2. Polderman, K. H., Schreuder, W. O., Strack van Schijndel, R. J. & Thijs, L. G. Hypernatremia in the intensive care unit: an indicator of quality of care? *Crit. Care Med.* **27**, 1105-1108, http://doi.org/10.1097/00003246-199906000-00029 (1999).

3. Hu, B. et al. Prognostic value of ICU-acquired hypernatremia in patients with neurological dysfunction. *Medicine (Baltimore)* **95**, e3840, http://doi.org/10.1097/MD.0000000000003840 (2016).

4. Imaizumi, T. et al. The association between intensive care unit-acquired hypernatraemia and mortality in critically ill patients with cerebrovascular diseases: a single-centre cohort study in Japan. *BMJ Open* **7**, e016248, http://doi.org/10.1136/bmjopen-2017-016248 (2017).

5. Lindner, G. & Funk, G. C. Hypernatremia in critically ill patients. *J. Crit. Care* **28**, 216 e11-20, http://doi.org/10.1016/j.jccr.2012.05.001 (2013).

6. Waite, M. D., Fuhrman, S. A., Badawi, O., Zuckerman, I. H. & Franey, C. S. Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay. *J. Crit. Care* **28**, 405-412, http://doi.org/10.1016/j.jccr.2012.11.013 (2013).

7. Sim, J. K., Ko, R. E., Na, S. J., Suh, G. Y. & Jeon, K. Intensive care unit-acquired hyponatremia in critically ill medical patients. *J. Transl. Med.* **18**, 268, http://doi.org/10.1186/s12967-020-02443-4 (2020).

8. O’Donoghue, S. D., Dulhunty, J. M., Bandeshe, H. K., Senthuran, S. & Gowardman, J. R. Acquired hypernatremia is an independent predictor of mortality in critically ill patients. *Anaesthesia* **64**, 514-520, http://doi.org/10.1111/j.1365-2044.2008.05857.x (2009).

9. Jeon, S. B., Koh, Y., Choi, H. A. & Lee, K. Critical care for patients with massive ischemic stroke. *J. Stroke* **16**, 146-160, http://doi.org/10.5853/jos.2014.16.3.146 (2014).

10. Qureshi, A. I. et al. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. *Crit. Care Med.* **26**, 440-446, http://doi.org/10.1097/00003246-199803000-00011 (1998).

11. Vedantam, A., Robertson, C. S. & Gopinath, S. P. Morbidity and mortality associated with hypernatremia in patients with severe traumatic brain injury. *Neurosurg. Focus* **43**, E2, http://doi.org/10.3171/2017.7.FOCUS17418 (2017).

12. Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease classification system. *Crit. Care Med.* **13**, 818-829 (1985).

13. Capuzzo, M. et al. Validation of severity scoring systems SAPS II and APACHE II in a single-center population. *Intensive Care Med.* **26**, 1779-1785, http://doi.org/10.1007/s001340000715 (2000).

14. Meredith, W., Rutledge, R., Fakhry, S. M., Emery, S. & Kromhout-Schiro, S. The conundrum of the Glasgow Coma Scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores. *J. Trauma* **44**, 839-844; discussion 844-845, http://doi.org/10.1097/00005373-199805000-00016 (1998).

15. Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm. Stat.* **10**, 150-161, http://doi.org/10.1002/pst.433 (2011).

16. Wells, D. L. et al. The relationship between serum sodium and intracranial pressure when using hypertonic saline to target mild hypernatremia in patients with head trauma. *Crit. Care* **16**, R193, http://doi.org/10.1186/cc11678 (2012).

17. Aiyagari, V., Deibert, E. & Diringer, M. N. Hypernatremia in the neurologic intensive care unit: how high is too high? *J. Crit. Care* **21**, 163-172, http://doi.org/10.1016/j.jccr.2005.10.002 (2006).

18. Li, M., Hu, Y. H. & Chen, G. Hypernatremia severity and the risk of death after traumatic brain injury. *Injury* **44**, 1213-1218, http://doi.org/10.1016/j.injury.2012.05.021 (2013).

19. Maggiore, U. et al. The relation between the incidence of hypernatremia and mortality in patients with severe traumatic brain injury. *Crit. Care* **13**, R110, http://doi.org/10.1186/cc7953 (2009).

20. Lindner, G. et al. Intensive care-acquired hypernatremia after major cardiothoracic surgery is associated with increased mortality. *Intensive Care Med.* **36**, 1718-1723, http://doi.org/10.1007/s00134-010-1968-4 (2010).
21. Darmon, M. et al. Association between hypernatraemia acquired in the ICU and mortality: a cohort study. Nephrol. Dial. Transplant. 25, 2510-2515, http://doi.org/10.1093/ndt/gfq067 (2010).

22. Ayus, J. C., Armstrong, D. L. & Arieff, A. I. Effects of hypernatraemia in the central nervous system and its therapy in rats and rabbits. J. Physiol. 492 (Pt 1), 243-255, http://doi.org/10.1113/jphysiol.1996.sp021305 (1996).

23. Kolmodin, L., Sekhon, M. S., Henderson, W. R., Turgeon, A. F. & Griesdale, D. E. Hypernatremia in patients with severe traumatic brain injury: a systematic review. Ann. Intensive Care 3, 35, http://doi.org/10.1186/2110-5820-3-35 (2013).

24. Beseoglu, K., Etminan, N., Steiger, H. J. & Hanggi, D. The relation of early hypernatremia with clinical outcome in patients suffering from aneurysmal subarachnoid hemorrhage. Clin. Neurol. Neurosurg. 123, 164-168, http://doi.org/10.1016/j.clineuro.2014.05.022 (2014).

**Figures**

![Study Flow Chart](image)

**Figure 1**

Study flow chart. ICU, intensive care unit; Na, sodium level.
Figure 2

Kaplan Meier survival analyses of propensity score-matched population (p < 0.001).